Glaukos Target of Unusually Large Options Trading (NYSE:GKOS)

Glaukos Corp (NYSE:GKOS) was the target of unusually large options trading on Monday. Stock traders bought 3,425 call options on the stock. This represents an increase of approximately 5,608% compared to the typical volume of 60 call options.

Glaukos stock traded up $1.43 during trading hours on Tuesday, hitting $64.24. The stock had a trading volume of 99,870 shares, compared to its average volume of 451,074. The company has a debt-to-equity ratio of 0.42, a current ratio of 6.32 and a quick ratio of 5.94. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of -173.62 and a beta of 1.68. Glaukos has a 1-year low of $50.60 and a 1-year high of $84.65. The stock’s fifty day moving average is $63.22 and its two-hundred day moving average is $68.81.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.07. The company had revenue of $58.51 million for the quarter, compared to analyst estimates of $56.96 million. Glaukos had a negative return on equity of 4.01% and a negative net margin of 8.60%. Glaukos’s revenue was up 33.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.17) earnings per share. As a group, sell-side analysts anticipate that Glaukos will post -0.4 EPS for the current year.

In other news, CFO Joseph E. Gilliam sold 3,750 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $68.50, for a total transaction of $256,875.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 15,512 shares of company stock valued at $990,672 in the last 90 days. Company insiders own 8.70% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Glaukos by 9.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,274 shares of the medical instruments supplier’s stock valued at $171,000 after acquiring an additional 201 shares during the last quarter. Lisanti Capital Growth LLC boosted its stake in shares of Glaukos by 1.1% during the second quarter. Lisanti Capital Growth LLC now owns 31,770 shares of the medical instruments supplier’s stock valued at $2,395,000 after acquiring an additional 340 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Glaukos by 0.9% during the second quarter. JPMorgan Chase & Co. now owns 46,720 shares of the medical instruments supplier’s stock valued at $3,544,000 after acquiring an additional 406 shares during the last quarter. NEXT Financial Group Inc boosted its stake in shares of Glaukos by 73.7% during the second quarter. NEXT Financial Group Inc now owns 1,129 shares of the medical instruments supplier’s stock valued at $85,000 after acquiring an additional 479 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Glaukos during the second quarter valued at $39,000. 96.56% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have recently commented on the company. ValuEngine upgraded Glaukos from a “buy” rating to a “strong-buy” rating in a research note on Friday. Bank of America cut Glaukos from a “buy” rating to an “underperform” rating and set a $67.00 price target for the company. in a research note on Monday, September 30th. Zacks Investment Research upgraded Glaukos from a “sell” rating to a “hold” rating and set a $76.00 price objective for the company in a research report on Thursday, September 12th. JPMorgan Chase & Co. set a $90.00 price objective on Glaukos and gave the stock a “buy” rating in a research report on Thursday, October 10th. Finally, Stifel Nicolaus cut their price objective on Glaukos from $73.00 to $69.00 and set a “hold” rating for the company in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $74.88.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.

Read More: What does a hold rating mean?

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.